{"disease":{"id":"lateral-canthal-lines","name":"Lateral canthal lines","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"incobotulinumtoxina","indication_name":"Moderate to severe lateral canthal lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Lateral canthal lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04157686","title":"MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":957,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT04225260","title":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":902,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT02248844","title":"Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT03732833","title":"MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT03721016","title":"MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT04247074","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT04622254","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT04594213","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT04249687","title":"Treatment of Moderate to Severe Lateral Canthal Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT04985916","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-210","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":false},{"nct_id":"NCT03785145","title":"MT10109L in the Treatment of Lateral Canthal Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT04143854","title":"Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT03923634","title":"Princess® RICH for the Correction of Fine Lines","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":false},{"nct_id":"NCT03655691","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-207","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":true},{"nct_id":"NCT03839693","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-208","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":true},{"nct_id":"NCT07492277","title":"A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":false},{"nct_id":"NCT03911102","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03326856","title":"ET-01 in Subjects With Lateral Canthal Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":true},{"nct_id":"NCT04259086","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03912805","title":"ET-01 in Subjects With Lateral Canthal Lines, LCL-209","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Eirion Therapeutics Inc.","has_results":true}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}